In recent months, we have highlighted key developments on Capitol Hill and discussed the implications of the change in Administration on the pace and focus of congressional investigations. With a Democratic majority now in both the House and the Senate, investigations targeting the private sector are primed to take center stage in the new Congress.
Drug Pricing Investigations in the 116th Congress
By Brian D. Smith, Gary Heimberg & Morgan Schreurs on
Posted in Congressional Investigations
Consistent with popular predictions and our prior posts, Congress made drug pricing a key item on its investigative agenda in the first year of the 116th Congress. Several factors contributed to the uptick in congressional drug pricing oversight activity, including the elevation of new Democratic chairs in the House with longstanding interests in drug…